United Therapeutics | UTHR - Debt


United Therapeutics reported $200M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Amarin USD 0 0 Mar/2025
Ardelyx USD 207.61M 968K Sep/2025
Baxter International USD 9.71B 13M Sep/2025
Bayer EUR 39.39B 1.31B Mar/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Gilead Sciences USD 24.94B 5M Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Insmed USD 727.89M 163.33M Dec/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
J&J USD 45.8B 4.97B Sep/2025
Lexicon Pharmaceuticals USD 99.26M 493K Sep/2023
Moderna USD 734M 7M Sep/2025
Omeros USD 442.16M 199K Sep/2023
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Teva Pharmaceutical Industries USD 17.07B 450M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025